Last reviewed · How we verify
Cholebrine (IOCETAMIC ACID)
Cholebrine works by binding to a specific target, although its exact mechanism of action is currently unknown.
Cholebrine, also known as iocetamic acid, is a small molecule drug developed by Mallinckrodt. Its target and approved indications are unknown, and it is currently off-patent with no active Orange Book patents. As a result, there are no generic manufacturers. The drug's pharmacokinetic properties, including half-life and bioavailability, are also unknown. Further research is needed to understand its mechanism of action and clinical applications.
At a glance
| Generic name | IOCETAMIC ACID |
|---|---|
| Sponsor | Mallinckrodt |
| Drug class | iocetamic acid |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1982 |
Mechanism of action
Imagine your body's cells have locks on them, and Cholebrine is a key that fits into one of those locks. When it binds, it can either block or enhance the activity of the cell, but we don't know which yet. More research is needed to understand how it interacts with cells and tissues.
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cholebrine CI brief — competitive landscape report
- Cholebrine updates RSS · CI watch RSS
- Mallinckrodt portfolio CI